Plasma Messenger RNAs Identified Through Bioinformatics Analysis are Novel, Non-Invasive Prostate Cancer Biomarkers

Figures & data

Figure 1 Schematic of experimental steps.

Table 1 Clinical Characteristics of Patients and Healthy Donors

	PCa Patients	Healthy Donors
Total	50	30
Age, mean±SD	65.7±6.9	64.3±7.5
Stage
I–II	30
III–IV	20
N
Negative	26
Positive	24
Gleason scores
≤6	27
>6	23

Figure 2 Heat map of differentially expressed genes in PCa compared with normal controls. (A) Top 20 over-expressed genes (red). (B) Top 20 under-expressed genes (blue).

Figure 3 Clinical validation of candidate biomarkers of PCa. PCA3, DLX1, DUOX1, and GSTP1 plasma mRNA expression in PCa compared with normal controls (Top); corresponding ROC analysis of PCA3, DLX1, DUOX1, and GSTP1 plasma mRNA expression in PCa (Bottom). *P < 0.05, **P < 0.01 vs control.

Figure 4 PCA3, DLX1, DUOX1, and GSTP1 expression in various cancers were analyzed. Red represents overexpression in various cancers compared with normal controls; blue represents underexpression in various cancers compared with normal controls.